Genemedi produces core diagnostic ingredients for test of Inflammation/autoimmune/inflammatory disease (MOG antibody disease) and related syndrome. GeneMedi offers paired diagnostics grade myelin oligodendrocyte glycoprotein (MOG) antibodies (monoclonal antibody, mab) and antigens for Inflammation/autoimmune/inflammatory disease (MOG antibody disease) rapid test kit of myelin oligodendrocyte glycoprotein (MOG) testing in standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for Inflammation/autoimmune/inflammatory disease (MOG antibody disease ) test are suitable for in functional ELISA, and other immunoassays in dignostics.The antibodies can act as a capture antibody and detection antibody. The antigens can be used as positive control.Myelin oligodendrocyte glycoprotein antibody disorders (MOGAD) is an idiopathic, inflammatory, demyelinating disease of the central nervous system (CNS). MOG is a glycoprotein uniquely expressed in oligodendrocytes in the CNS. MOG antibodies were originally thought to be involved in multiple sclerosis (MS), but subsequent studies found it to be a distinct disease. MOGAD have many similarities to neuromyelitis optica but several studies have demonstrated they have unique clinical features, treatment response, and prognosis. MOGAD were initially identified in NMOSD antibody negative patients. Pathologically NMOSD is classified as am astrocytopathy, while MOGAD are classified as oligodendrogliopathies. The MOG antibody can distinguish a spectrum of autoimmune demyelinating diseases from multiple sclerosis (MS). Testing positive for the MOG antibody indicates that a patient doesn’t have classical MS. That’s important because diseases associated with the MOG antibody — as well as diseases associated with the water channel aquaporin-4 (AQP4) antibody, which was discovered at Mayo Clinic — are commonly misdiagnosed as MS. Yet some MS medications have been reported to worsen diseases that mimic MS. Which patients would benefit from this antibody testing? Any patient who suddenly presents with vision loss, significant disk edema or recurrent optic neuritis should consider testing for both MOG and AQP4 antibodies. Patients who have more than one episode of optic neuritis absolutely should have testing. An optic neuritis seems to be a very common presentation of MOG.